Drugs / V181
V181
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05710224 | Feb 2023 → Jan 2024 | dengue disease | Butantan Institute | Completed | No outcome recorded |
| Phase 2 | NCT05507450 | Sep 2022 → Jun 2023 | dengue disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07013487 | Jun 2025 → Oct 2031 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V181 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07013487 ↗ |
| Known as | Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated] | “V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated])” NCT05710224 ↗1“V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated])” NCT05507450 ↗ |
| Known as | rDENVΔ30 | “V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated])” NCT05507450 ↗ |
| Modality | Vaccine | “Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]” NCT05507450 ↗ |
| Route | Subcutaneous | “0.5mL subcutaneous (SC) dose of V181 High-Potency vaccine” NCT05507450 ↗ |